The ClinicianThe ClinicianКлиницист1818-83382412-8775Publishing House ABV Press11210.17650/1818-8338-2011-3-109-111CLINICAL CASES AWARDS FROM THE YOUNG CARDIOLOGISTS' WORKING GROUPКОНКУРС КЛИНИЧЕСКИХ СЛУЧАЕВ РАБОЧЕЙ ГРУППЫ МОЛОДЫХ КАРДИОЛОГОВ ВНОКPOLYCHEMOTHERAPY INDUCED CARDIOMYOPATHY IN PATIENT WITH BREAST CANCERКАРДИОМИОПАТИЯ, ИНДУЦИРОВАННАЯ ПОЛИХИМИОТЕРАПИЕЙ, У БОЛЬНОЙ РАКОМ МОЛОЧНОЙ ЖЕЛЕЗЫKorneevaO. N.КорнееваО. Н.
Russian Federation
doctorok@land.ruDrapkinaO. M.ДрапкинаО. М.
Russian Federation
KozlovaE. V.КозловаЕ. В.
Russian Federation
IvashkinV. T.ИвашкинВ. Т.
Russian Federation
I.M. Sechenov First Moscow State Medical UniversityГОУ ВПО ПМГМУ имени И.М. Сеченова15072011531091111707201417072014Copyright ©; 2011, Korneeva O.N., Drapkina O.M., Kozlova E.V., Ivashkin V.T.Copyright ©; 2011, Корнеева О.Н., Драпкина О.М., Козлова Е.В., Ивашкин В.Т.2011Korneeva O.N., Drapkina O.M., Kozlova E.V., Ivashkin V.T.Корнеева О.Н., Драпкина О.М., Козлова Е.В., Ивашкин В.Т.https://creativecommons.org/licenses/by/4.0https://klinitsist.abvpress.ru/Klin/article/view/112

Clinical observation of the patient with dilated cardiomyopathy, developed after chemotherapy for breast cancer.

Представлено клиническое наблюдение пациентки с дилатационной кардиомиопатией, развившейся после проведения химиотерапии по поводу рака молочной железы.

breast cancerdilated cardiomyopathychemotherapyрак молочной железыдилатационная кардиомиопатия,химиотерапия1. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al.; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659–72.Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al.; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659–72.2. Smith I., Procter M., Gelber R.D., et al.; HERA study team. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29–36.Smith I., Procter M., Gelber R.D., et al.; HERA study team. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29–36.3. Miolo G.M., Mura N.L., Nigri P., et al. The cardiotoxicity of chemotherapy: New prospects for an old problem. Radiol Oncol 2006;40(3):149–61.Miolo G.M., Mura N.L., Nigri P., et al. The cardiotoxicity of chemotherapy: New prospects for an old problem. Radiol Oncol 2006;40(3):149–61.